NYSE:GLS - New York Stock Exchange, Inc. - US36850R2040 - Common Stock - Currency: USD
0.1586
+0 (+0.38%)
The current stock price of GLS is 0.1586 USD. In the past month the price decreased by -33.92%. In the past year, price decreased by -96.82%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.
GELESIS HOLDINGS INC
501 Boylston Street, Suite 6102
Boston MASSACHUSETTS US
Employees: 93
Company Website: https://capstarspac.com/
Phone: 18573277737.0
The current stock price of GLS is 0.1586 USD. The price increased by 0.38% in the last trading session.
The exchange symbol of GELESIS HOLDINGS INC is GLS and it is listed on the New York Stock Exchange, Inc. exchange.
GLS stock is listed on the New York Stock Exchange, Inc. exchange.
8 analysts have analysed GLS and the average price target is 0.46 USD. This implies a price increase of 189.41% is expected in the next year compared to the current price of 0.1586. Check the GELESIS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GELESIS HOLDINGS INC (GLS) has a market capitalization of 11.63M USD. This makes GLS a Nano Cap stock.
GELESIS HOLDINGS INC (GLS) currently has 93 employees.
GELESIS HOLDINGS INC (GLS) has a resistance level at 0.17. Check the full technical report for a detailed analysis of GLS support and resistance levels.
The Revenue of GELESIS HOLDINGS INC (GLS) is expected to grow by 80.41% in the next year. Check the estimates tab for more information on the GLS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLS does not pay a dividend.
GELESIS HOLDINGS INC (GLS) will report earnings on 2023-05-10, before the market open.
GELESIS HOLDINGS INC (GLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).
ChartMill assigns a fundamental rating of 2 / 10 to GLS. GLS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months GLS reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 45% to GLS. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 78.59% and a revenue growth 80.41% for GLS